Information Provided By:
Fly News Breaks for September 7, 2016
RARE
Sep 7, 2016 | 07:38 EDT
SunTrust analyst Edward Nash says it's "likely" that Ultragenyx's KRN23 drug hit its phosphorus and rickets endpoints in a Phase II study. The analyst says he holds this view because of "the clear biology of the disease, the mechanism of the drug, and robust clinical data presented to date." Nash notes that the data is slated to be presented at a September 16-19 conference. He reiterates a $100 price target and Buy rating on the shares.
News For RARE From the Last 2 Days
There are no results for your query RARE